, Tracking Stock Market Picks
Enter Symbol:
Celgene Corporation (CELG) [hlAlert]

up 280.98 %

Celgene Corporation (CELG) rated Buy with price target $89 by Lazard Capital

Posted on: Wednesday,  Jul 2, 2008  8:25 AM ET by Lazard Capital

Lazard Capital rated Buy Celgene Corporation (NASDAQ: CELG) on 07/02/2008. Previously Lazard Capital rated Buy Celgene Corporation (NASDAQ: CELG) on 11/19/2007.,
when the stock price was $32.30. Since then, Celgene Corporation has gained 280.99% as of 01/14/2016's recent price of $123.04.
If you would have followed the previous Lazard Capital's recommendation on CELG, you would have gained 280.98% of your investment in 2978 days.

Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/2/2008 8:25 AM Buy
34.33 44.50
as of 12/24/2008
1 Week up  4.07 %
1 Month down  -13.96 %
3 Months down  -19.55 %
1 YTD down  -27.89 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/10/2008 11:25 AM Buy
27.81 38.50
11/19/2007 11:25 AM Buy
32.30 37.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy